14 February 2018
MSD Animal Health Names 2018 High Quality Pork Ph.D. Award Recipient
Award winner to present at multiple meetings with industry experts
Madison, NJ, February 14, 2018 – MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is proud to announce that Ana Carolina Lopes-Antunes, DVM, Ph.D., is the recipient of the 2018 High Quality Pork Ph.D. Award in support of research in swine health, production and welfare.
Ana Lopes-Antunes, a post-doctoral researcher from the Division for Diagnostics and Scientific Advice - Epidemiology, National Veterinary Institute, Technical University in Denmark, will be given the opportunity to present her research to an impressive number of swine industry specialists at upcoming MSD Animal Health High Quality Pork meetings to be held in Asia, Latin America and Europe in 2018.
The company also awarded honorable mentions to Marisa Rotolo, Ph.D. in Veterinary Microbiology, and a post-doctoral researcher at Iowa State University, and the U.S.D.A. Center for Epidemiology and Animal Health, and Pablo Valdes-Donoso, DVM, MPVM, MS, Ph.D., a post-doctoral scholar at the University of California, Davis.
Dr. Lopes-Antunes’ research project focused on exploring large volumes of swine-related databases for endemic swine diseases in Denmark, in order to monitor, control and eradicate these diseases, using PRRS (porcine reproductive and respiratory syndrome), as an example.
She is originally from Portugal where she obtained her DVM and MSc in Veterinary Medicine at University of Lisbon and was awarded a Ph.D. from the Technical University in Denmark, where she is currently a post-doctoral researcher.
“We are pleased to recognize Ana’s research as part of our commitment to advance the future of young veterinarians and veterinary scientists and our company’s mission, the Science of Healthier Animals™,” said Rika Jolie, DVM, Ph.D., MBA, Global Technical Director, Swine, MSD Animal Health. “We believe this opportunity will help prepare graduate students for their vital roles within our industry and it is our hope to establish life-long partnerships with them to further ongoing research and innovation.”
Dr. Lopes-Antunes was selected among several candidates who defended their doctoral (Ph.D.), research in either veterinary or animal science with an emphasis on swine within the last 12 months.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).